Balanced news tone
News Sentiment
RXRX sentiment intelligence
RECURSION PHARMACEUTICALS INC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
91/100 classification confidence.
directly relevant articles
high-authority source matches
-15.2% over one week, -4.9% over four weeks, trend inactive, and below fair value.
Recursion Pharmaceuticals Stock Short Interest Falls to 34.41%
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Recursion Pharmaceuticals Stock Short Interest Falls to 34.41%
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 21 Jul 2026 13:28
- Source
- Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 20 Jul 2026 21:50
- Source
- Market source
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Jul 2026 14:24
- Source
- Stocktwits
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 21:50
- Source
- Market source
Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 17:37
- Source
- Quiver Quantitative
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 07:00
- Source
- Market source
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Market source
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Jul 2026 07:00
- Source
- The Motley Fool
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- The Motley Fool
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- The Motley Fool
Recursion Pharmaceuticals Stock (RXRX) Opinions on ARK Invest's Recent Share Purchase
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 07:00
- Source
- Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Market source
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 07:00
- Source
- Market source
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jun 2026 07:00
- Source
- Market source
Morgan Stanley Raises its Price Target on Recursion (RXRX)
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 22 May 2026 07:00
- Source
- Market source
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Market source
RXRX Stock: Why Did Nvidia Offload AI Drug Developer Recursion?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Mar 2026 07:00
- Source
- CMC Markets
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has 'Reached An Inflection Point'
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Feb 2026 08:00
- Source
- Menafn
Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Feb 2026 08:00
- Source
- Barchart.com
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Dec 2025 08:00
- Source
- Barchart.com
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Dec 2025 08:00
- Source
- Stocktwits
Recursion Pharmaceuticals Stock: Growth or Bubble?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Oct 2025 07:00
- Source
- StocksToTrade
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2025 07:00
- Source
- 24/7 Wall St.
Recursion Pharmaceuticals Stock Price Forecast. Should You Buy RXRX?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 27 Apr 2021 19:48
- Source
- StockInvest.us
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2021 07:00
- Source
- PR Newswire
Recursion Pharmaceuticals Jumps in Debut After $436 Million IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2021 07:00
- Source
- Bloomberg.com